229 related articles for article (PubMed ID: 31398384)
1. Relationship of clinical adverse event reports to models of arrhythmia risk.
Ether N; Leishman D; Bailie M; Lauver A
J Pharmacol Toxicol Methods; 2019; 100():106622. PubMed ID: 31398384
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
3. Computational approaches to understand the adverse drug effect on potassium, sodium and calcium channels for predicting TdP cardiac arrhythmias.
Sharifi M
J Mol Graph Model; 2017 Sep; 76():152-160. PubMed ID: 28756335
[TBL] [Abstract][Full Text] [Related]
4. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Teng C; Walter EA; Gaspar DKS; Obodozie-Ofoegbu OO; Frei CR
Int J Med Sci; 2019; 16(7):1018-1022. PubMed ID: 31341415
[No Abstract] [Full Text] [Related]
5. A 2015 focus on preventing drug-induced arrhythmias.
Bossu A; van der Heyden MA; de Boer TP; Vos MA
Expert Rev Cardiovasc Ther; 2016; 14(2):245-53. PubMed ID: 26560188
[TBL] [Abstract][Full Text] [Related]
6. Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.
Farkas AS; Nattel S
Drugs; 2010 Mar; 70(5):573-603. PubMed ID: 20329805
[TBL] [Abstract][Full Text] [Related]
7. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
8. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.
Kao DP; Haigney MC; Mehler PS; Krantz MJ
Addiction; 2015 Sep; 110(9):1468-75. PubMed ID: 26075588
[TBL] [Abstract][Full Text] [Related]
9. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
10. The Electro-Mechanical window: a risk marker for Torsade de Pointes in a canine model of drug induced arrhythmias.
van der Linde HJ; Van Deuren B; Somers Y; Loenders B; Towart R; Gallacher DJ
Br J Pharmacol; 2010 Dec; 161(7):1444-54. PubMed ID: 21054337
[TBL] [Abstract][Full Text] [Related]
11. A new preclinical biomarker for risk of Torsades de Pointes: drug-induced reduction of the cardiac electromechanical window.
Vargas HM
Br J Pharmacol; 2010 Dec; 161(7):1441-3. PubMed ID: 20698854
[TBL] [Abstract][Full Text] [Related]
12. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
Guns PJ; Johnson DM; Weltens E; Lissens J
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
[TBL] [Abstract][Full Text] [Related]
13. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
14. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
Fermini B; Hancox JC; Abi-Gerges N; Bridgland-Taylor M; Chaudhary KW; Colatsky T; Correll K; Crumb W; Damiano B; Erdemli G; Gintant G; Imredy J; Koerner J; Kramer J; Levesque P; Li Z; Lindqvist A; Obejero-Paz CA; Rampe D; Sawada K; Strauss DG; Vandenberg JI
J Biomol Screen; 2016 Jan; 21(1):1-11. PubMed ID: 26170255
[TBL] [Abstract][Full Text] [Related]
15. An overview of QT interval assessment in safety pharmacology.
Lacroix P; Picard S
Curr Protoc Pharmacol; 2006 Jul; Chapter 10():Unit10.7. PubMed ID: 22294169
[TBL] [Abstract][Full Text] [Related]
16. Utility of Normalized TdP Score System in Drug Proarrhythmic Potential Assessment: A Blinded in vitro Study of CiPA Drugs.
Liu T; Liu J; Lu HR; Li H; Gallacher DJ; Chaudhary K; Wang Y; Yan GX
Clin Pharmacol Ther; 2021 Jun; 109(6):1606-1617. PubMed ID: 33283267
[TBL] [Abstract][Full Text] [Related]
17. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
Meyer-Massetti C; Cheng CM; Sharpe BA; Meier CR; Guglielmo BJ
J Hosp Med; 2010 Apr; 5(4):E8-16. PubMed ID: 20394022
[TBL] [Abstract][Full Text] [Related]
18. Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.
Patel N; Hatley O; Berg A; Romero K; Wisniowska B; Hanna D; Hermann D; Polak S
AAPS J; 2018 Mar; 20(3):47. PubMed ID: 29541956
[TBL] [Abstract][Full Text] [Related]
19. Drug-Induced QT Prolongation and Torsades de Pointes: An All-Exclusive Relationship or Time for an Amicable Separation?
Hondeghem LM
Drug Saf; 2018 Jan; 41(1):11-17. PubMed ID: 28853038
[TBL] [Abstract][Full Text] [Related]
20. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium.
Sager PT; Gintant G; Turner JR; Pettit S; Stockbridge N
Am Heart J; 2014 Mar; 167(3):292-300. PubMed ID: 24576511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
